Sunesis Pharmaceuticals (SNSS) Sees Unusually-High Trading Volume

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) saw strong trading volume on Wednesday . 1,611,440 shares changed hands during trading, an increase of 140% from the previous session’s volume of 672,449 shares.The stock last traded at $0.56 and had previously closed at $0.53.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Saturday. ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, HC Wainwright assumed coverage on Sunesis Pharmaceuticals in a report on Thursday, December 20th. They set a “neutral” rating and a $0.50 target price on the stock. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $1.75.

The firm has a market capitalization of $17.66 million, a PE ratio of -0.37 and a beta of 2.57.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, equities research analysts forecast that Sunesis Pharmaceuticals, Inc. will post -0.81 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at

Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Read More: What is a Stop Order?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply